- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04275193
The Safety and Efficacy of Zishenqing in Subjects With Active Systemic Lupus Erythematosus
April 26, 2020 updated by: maojianchun, Shanghai University of Traditional Chinese Medicine
The Safety and Efficacy of the Traditional Chinese Medicine Zishenqing in Subjects With Active Systemic Lupus Erythematosus
This study evaluates the safety and efficacy of the traditional chinese medicine Zishenqing in the treatment of active systemic lupus erythematosus.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
This study will be a multicenter, randomized, double-blind, placebo parallel controlled clinical trial with a course of 12 weeks.
- Multicenter: During the study period, it will be decided whether to increase the improvement progress of the research unit according to whether it will be difficult to join the group and the overall progress, so as to complete the clinical study on time in accordance with the research plan.
- Random scheme: In this study, a dynamic random variance minimization random scheme will be adopted. Considering the two influencing factors of SLEDAI score and complement level, the DAS for Interactive Web Response System(IWRS) will be used to calculate and distribute random numbers and dispensing drugs.
- Control drug: Placebo will be used as control in this trial.
- Blind method: The Zishenqing simulator will be prepared by double-blind design, the dosage form, appearance, size, color and smell will be consistent with the experimental drug, and the test process will be in a double-blind state.
Study Type
Interventional
Enrollment (Anticipated)
118
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jianchun Mao, Master
- Phone Number: +8618917763231
- Email: mjczyczx@163.com
Study Contact Backup
- Name: Zhujing Zhu, Ph.D
- Phone Number: +8613816914874
- Email: zzj01@hotmail.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200030
- Recruiting
- Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine
-
Contact:
- Jianchun Mao, master
- Phone Number: 86-18917763231
- Email: mjcct2018@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients who qualify for the diagnosis of systemic lupus erythematosus according to the American college of rheumatology's 1997 revised classification criteria for systemic lupus erythematosus;
- For inpatient or out-patient with good compliance, sign the informed consent before the test;
- Sledai score during screening period≤10;
- Maintain a stable standard treatment regimen for at least 30 days before the first day (that is, the date of administration of the intervention drug). Standard treatment regimens refer to the stable use of any of the following (alone or in combination): corticosteroids, hydroxychloroquine, non-steroidal anti-inflammatory drugs, other immunosuppressants or immunomodulators (including azathioprine, mycophenolate ester, cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine);
Exclusion Criteria:
- Severe lupus nephritis requiring hemodialysis or high-dose glucocorticoid treatment in the last 2 months;
- Central nervous system diseases (including epilepsy, psychosis, organic encephalopathy syndrome, cerebrovascular accident, encephalitis, central nervous system vasculitis) caused by SLE or non-SLE in the last 2 months;
Patients with severe heart, liver and kidney diseases and disease history of important organs, blood and endocrine system;
Evaluation criteria of severity:
- Alanine aminotransferase(ALT) and Aspartate aminotransferase(AST)≥3 times the upper limit of normal;
- Glomerular filtration rate(GFR)<30ml/min;
- White Blood Cell(WBC)<2.0×10^9/l;
- Platelet(PLT)<50×10^9/l;
- Immunodeficiency, uncontrolled infection and active or recurrent peptic ulcer;
- Pregnant and lactating women;
- Anaphylaxis: allergic to traditional Chinese medicine;
- The investigator considered it inappropriate to participate in this study;
- Participate in other clinical trials during the screening period.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Zishenqing
The original treatment and Zishenqing 1Co by mouth,twice a day for 12 weeks
|
Zishenqing Granule
Other Names:
|
Placebo Comparator: Placebo
The original treatment and Zishenqing simulator 1Co by mouth,twice a day for 12 weeks
|
Granule manufactured to mimic Zishenqing(containing 10% composition)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lupus Quality of Life (LupusQoL)
Time Frame: 12weeks
|
Self reported the quality of life in patients with systemic lupus erythematosus.LupusQoL is made up of five parts((physical health, pain, planning, emotional health, and fatigue) and has a total of 34 questions.Each question is scored0-4,yielding a total between 0 and 136.
|
12weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The 36-item shot form health survey(SF-36)
Time Frame: 12weeks
|
As a concise health questionnaire, SF-36 comprehensively summarizes the quality of life of the subjects from eight aspects: physiological function, physiological function, physical pain, general health status, energy, social function, emotional function and mental health.
|
12weeks
|
Systemic lupus erythematosus disease activity index(SLEDAI)
Time Frame: 12weeks
|
SLEDAI scores are used to determine the activity of SLE.SLEDAI consists of 24 clinical and laboratory projects with different weights(0:no activity;1-5:mild activity;6-10:moderate activity;11-19:severe activity;≥20:extremely severe activity).
|
12weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Chair: Liangjing Lv, Ph.D, RenJi Hospital
- Study Chair: Huanru Qu, Ph.D, Longhua Hospital
- Study Chair: Zhujing Zhu, Ph.D, Longhua Hospital
- Study Chair: Ruru Guo, Ph.D, RenJi Hospital
- Study Chair: Zhongping Xu, Master, Longhua Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 22, 2019
Primary Completion (Anticipated)
March 1, 2022
Study Completion (Anticipated)
September 1, 2022
Study Registration Dates
First Submitted
February 12, 2020
First Submitted That Met QC Criteria
February 17, 2020
First Posted (Actual)
February 19, 2020
Study Record Updates
Last Update Posted (Actual)
April 28, 2020
Last Update Submitted That Met QC Criteria
April 26, 2020
Last Verified
April 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Zishenqing
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Lupus Erythematosus
-
SanofiCompletedCutaneous Lupus Erythematosus-Systemic Lupus ErythematosusJapan
-
Kyowa Kirin Co., Ltd.RecruitingHealthy Volunteers | Systemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)Japan
-
Second Xiangya Hospital of Central South UniversityNational Natural Science Foundation of China; Hunan Provincial Natural Science... and other collaboratorsActive, not recruitingCutaneous Lupus Erythematosus | Systemic Lupus Erythematosus RashChina
-
Novartis PharmaceuticalsNot yet recruitingSystemic Lupus Erythematosus, SLE
-
Changhai HospitalRui Therapeutics Co., LtdRecruitingSystemic Lupus Erythematosus (SLE)China
-
Bioray LaboratoriesFirst Affiliated Hospital of Zhejiang UniversityRecruitingSystemic Lupus Erythematosus (SLE)China
-
Sohag UniversityNot yet recruitingSystemic Lupus Erythematosus (SLE)
-
AbbVieCompletedSystemic Lupus Erythematosus (SLE)United States, Argentina, Australia, Bulgaria, China, Colombia, Germany, Hungary, Italy, Japan, Korea, Republic of, Mexico, New Zealand, Poland, Puerto Rico, Spain, Taiwan, United Kingdom
-
AmgenTerminatedActive Systemic Lupus ErythematosusKorea, Republic of, United States, Taiwan, Canada, Spain, Italy, Mexico, Japan, Turkey, Austria, Greece, Colombia, Switzerland, Poland, France, Bulgaria, Hong Kong, Russian Federation, Chile
-
BiogenEnrolling by invitationSystemic Lupus Erythematosus (SLE)United States, China, Belgium, Korea, Republic of, Netherlands, Spain, Greece, Australia, Italy, Bulgaria, Hungary, France, Serbia, Argentina, Mexico, Brazil, Poland, Taiwan, Germany, Philippines, Sweden, Czechia, Chile, Russian Federation and more